(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 July 2011 (07.07.2011)

PCT

(10) International Publication Number
WO 2011/080510 A1

(51) International Patent Classification:
C07D 487/14 (2006.01) *A61K 31/5025* (2006.01)
C07D 491/14 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/GB2010/002348

(22) International Filing Date:
31 December 2010 (31.12.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09380202.3 31 December 2009 (31.12.2009) EP

(71) Applicant *(for all designated States except US)*: **CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO)** [ES/ES]; Melchor Fernández, Almagro 3, E-28029 Madrid (ES).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GARCIA COLLAZO, Ana Maria** [ES/ES]; Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández, Almagro 3, E-28029 Madrid (ES). **PASTOR FERNÁNDEZ, Joaquín** [ES/ES]; Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández, Almagro 3, E-28029 Madrid (ES). **BLANCO APARICIO, Carmen** [ES/ES]; Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández, Almagro 3, E-28029 Madrid (ES). **RODRÍGUEZ HERGUETA, Antonio** [ES/ES]; Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández, Almagro 3, E-28029 Madrid (ES). **MARTÍN HERNANDO, José Ignacio** [ES/ES]; Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández, Almagro 3, E-28029 Madrid (ES). **RAMOS LIMA, Francisco Javier** [ES/ES]; Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández, Almagro 3, E-28029 Madrid (ES). **HERNÁNDEZ HIGUERAS, Ana Isabel** [ES/ES]; Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández, Almagro 3, E-28029 Madrid (ES). **SALUSTE, Carl-Gustave Pierre** [SE/ES]; Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández, Almagro 3, E-28029 Madrid (ES). **GONZÁLEZ CANTALAPIEDRA, Esther** [ES/ES]; Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández, Almagro 3, E-28029 Madrid (ES). **MARTÍNEZ GONZÁLEZ, Sonia** [ES/ES]; Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández, Almagro 3, E-28029 Madrid (ES). **SALGADO SERRANO, Antonio** [ES/ES]; Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández, Almagro 3, E-28029 Madrid (ES). **NOYA MARIÑO, Beatriz** [ES/ES]; Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández, Almagro 3, E-28029 Madrid (ES).

(74) Agent: **MCNEENEY, Stephen**; Potter Clarkson LLP, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(54) Title: TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS



(I)

(57) Abstract: There is provided compounds of formula (I), wherein R^1, R^2, R^3 and R^4 have meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceuticaöy-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PlM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. There is also provided combinations comprising the compounds of formula (I).

WO 2011/080510 A1